Loading…
Ascendis Pharma A/S is projected to rise to $321.57 by 2027, a +28% move from its current price of $251.07. ASND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $246.98 | $251.15 | $255.38 | +0.03% |
| Aug 2 | $245.35 | $251.22 | $257.24 | +0.06% |
| Aug 3 | $244.13 | $251.30 | $258.69 | +0.09% |
| Aug 4 | $243.11 | $251.38 | $259.93 | +0.12% |
| Aug 5 | $242.23 | $251.46 | $261.04 | +0.15% |
| Aug 6 | $241.44 | $251.53 | $262.05 | +0.18% |
| Aug 7 | $240.72 | $251.61 | $263.00 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $240.72 | $251.61 | $263.00 | +0.22% |
| Week 2 | $236.86 | $252.15 | $268.44 | +0.43% |
| Week 3 | $234.05 | $252.70 | $272.83 | +0.65% |
| Week 4 | $231.79 | $253.24 | $276.68 | +0.87% |
| Week 5 | $229.88 | $253.79 | $280.19 | +1.08% |
| Week 6 | $228.21 | $254.34 | $283.46 | +1.30% |
| Week 7 | $226.72 | $254.89 | $286.55 | +1.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. This positions it in the healthcare sector. The company offers SKYTROFA for pediatric growth hormone deficiency and YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism, and it is developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focusing on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.
ASND is a healthcare stock with a current price of $253.86. It trades in the healthcare sector under the ASND ticker. The asset has a market capitalization of $16.65B and a market rank of 636.
The forecast suggests a long-run bullish path, with yearly averages climbing over time—from a 2026 average of $253.86 to a 2050 average of $2,982.71 and a 2050 max of $4,910.44. This implies meaningful upside across the multi-year horizon, with higher potential in later years such as 2040 and 2050.
A major floor 19.2% below — a decisive break under it would weaken the trend.
The nearest floor, 9.2% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 20.0% above — clearing it would confirm fresh momentum.
Key ASND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $252.97 | Sell | $252.72 | Sell |
| MA 10 | $253.74 | Sell | $254.64 | Sell |
| MA 20 | $261.45 | Sell | $255.28 | Sell |
| MA 50 | $244.50 | Buy | $248.63 | Buy |
| MA 100 | $238.14 | Buy | $240.05 | Buy |
| MA 200 | $226.04 | Buy | $225.92 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.75 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -87.86 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -2.40 | Sell |
| ROC (12) | -5.46 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 32.75 | Neutral |
| Momentum (10) | -8.73 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 252.52 | Sell |
| ADX (14) | 14.67 | Neutral |
| ATR (14) | 3.39 | Info |
The short-term technical picture is bullish. The RSI(14) is 50, with the 50-day simple moving average at $243.30 and the 200-day simple moving average at $224.99. Immediate support is at $209.79 and resistance at $277.18. Over the past 30 days, the range has been from $223.53 to $288.31, and the security exhibits an annualized volatility of 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $202.99 | $251.07 | $336.85 | 0% | Neutral | |
| $263.66 | $321.57 | $409.82 | +28% | Bullish | |
| $336.34 | $418.02 | $547.38 | +66% | Bullish | |
| $381.95 | $482.09 | $644.86 | +92% | Bullish | |
| $400.13 | $511.90 | $697.17 | +104% | Bullish | |
| $459.03 | $594.45 | $822.47 | +137% | Bullish | |
| $483.57 | $633.34 | $888.81 | +152% | Bullish | |
| $511.23 | $676.64 | $961.92 | +170% | Bullish | |
| $628.39 | $840.00 | $1,208.49 | +235% | Bullish | |
| $718.65 | $969.77 | $1,410.77 | +286% | Bullish | |
| $981.73 | $1,381.85 | $2,106.92 | +450% | Bullish | |
| $2,003.33 | $3,024.47 | $4,943.71 | +11.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $202.99 | $251.07 | $292.57 | +0.00% |
| August 2026 | $222.16 | $259.04 | $307.82 | +3.18% |
| September 2026 | $220.19 | $258.22 | $309.73 | -0.32% |
| October 2026 | $218.94 | $257.93 | $311.68 | -0.11% |
| November 2026 | $226.22 | $267.51 | $325.21 | +3.72% |
| December 2026 | $232.25 | $275.59 | $336.85 | +3.02% |
Click any year to see its month-by-month ASND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ascendis Pharma A/S's 2026 outlook centres on $251.07, within a $202.99 to $336.85 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ASND could reach as high as $409.82, with a base case around $321.57 and support toward $263.66 — roughly +28% from $251.07. Momentum favours further upside here.
Expect ASND to range from $336.34 to $547.38 through 2028. The $418.02 average target implies a +66% move from current prices. That is up +30% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The ASND price prediction for 2029 points to an average of $482.09 (low $381.95, high $644.86) — a potential gain of +92% on today's $251.07. Momentum favours further upside here.
In 2030, ASND is projected to trade between $400.13 and $697.17, averaging $511.90 — a potential gain of +104% from today's $251.07. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Ascendis Pharma A/S's 2031 outlook centres on $594.45, within a $459.03 to $822.47 range. That is up +16% on the projected 2030 average. That marks a +137% change versus current levels. Momentum favours further upside here.
By 2032, ASND could reach as high as $888.81, with a base case around $633.34 and support toward $483.57 — roughly +152% from $251.07. Buyers look set to stay in control over this stretch.
Expect ASND to range from $511.23 to $961.92 through 2033. The $676.64 average target implies a +170% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The ASND price prediction for 2034 points to an average of $840.00 (low $628.39, high $1,208.49) — a potential gain of +235% on today's $251.07. Buyers look set to stay in control over this stretch.
In 2035, ASND is projected to trade between $718.65 and $1,410.77, averaging $969.77 — a potential gain of +286% from today's $251.07. That is up +15% on the projected 2034 average. Momentum favours further upside here.
Ascendis Pharma A/S's 2040 outlook centres on $1,381.85, within a $981.73 to $2,106.92 range. That is up +42% on the projected 2035 average. That marks a +450% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ASND could reach as high as $4,943.71, with a base case around $3,024.47 and support toward $2,003.33 — roughly +11.0x from $251.07. Momentum favours further upside here.
Investing $1,000 in ASND today (≈ 3.982953 ASND) could be worth
$12,046.31
+$11,046.31 (+1105%) by 2050 · US Dollar
Based on the average projected ASND price of $3,024.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASNDwould be worth at today's price.
$1,000 invested in ASND on Jul 30, 2025 (≈ 5.995923 ASND) would be worth
$1,505.4
+$505.4 (+50.5%) today · 1.51× · US Dollar
Based on a ASND entry price of $166.78 vs. today's $251.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $252.66 | $993.71 | -0.6% |
| 1 month ago | $266.72 | $941.32 | -5.9% |
| 3 months ago | $220.93 | $1,136.42 | +13.6% |
| 6 months ago | $226.1 | $1,110.44 | +11.0% |
| 1 year ago | $166.78 | $1,505.4 | +50.5% |
| All time (5.0y) ago | $120.34 | $2,086.34 | +108.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASND forecast.
Our base-case forecast reaches $500.00 around 2030.
Implied market cap at $500.00: $32.8B
In 2030, the forecast sees an average price of $512.95 with a minimum of $399.79 and a maximum of $701.27, delivering a 102.1% ROI and a bullish sentiment. In 2040, the average price is forecast at $1,374.00 with a minimum of $970.70 and a maximum of $2,107.41, showing a 441.2% ROI and a bullish sentiment. By 2050, the average is projected at $2,982.71 with a minimum of $1,960.37 and a maximum of $4,910.44, representing a 1074.9% ROI and a bullish sentiment.
The overall multi-year trajectory is clearly positive, but these are estimates and not guarantees, and actual results may differ due to market conditions and other factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $512.95, a minimum of $399.79, and a maximum of $701.27, with a 102.1% ROI and a bullish sentiment.
The forecast depicts a bullish sentiment across multiple years, with steadily rising averages: 2027 avg $324.38 (ROI 27.8%), 2028 avg $421.38 (ROI 66%), 2029 avg $483.39 (ROI 90.4%), 2030 avg $512.95 (ROI 102.1%), continuing to 2050 avg $2,982.71 (ROI 1074.9%). These are estimates and not guarantees.
Yes. The 2035 max is $1,409.91 and the 2040 max is $2,107.41, indicating that surpassing $1,000 is projected in the mid-to-late horizon (2035 or later) based on the forecasted ranges.
The sentiment is bullish. RSI(14) is 50. SMA(50) is $243.30 and SMA(200) is $224.99. Support is at $209.79 and resistance at $277.18. The 30-day range runs from $223.53 to $288.31, and annualized volatility is 40%.
The current price is $253.86. The market capitalization is $16.65B, and the stock is ranked 636 by market capitalization.
Ascendis Pharma A/S Community Discussion
0Share your Ascendis Pharma A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.